HC Wainwright Comments on Kronos Bio, Inc.’s FY2023 Earnings (NASDAQ:KRON)

Kronos Bio, Inc. (NASDAQ:KRONGet Rating) – HC Wainwright issued their FY2023 EPS estimates for Kronos Bio in a report issued on Friday, November 18th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($2.16) for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Kronos Bio’s current full-year earnings is ($2.49) per share.

KRON has been the subject of a number of other reports. Berenberg Bank started coverage on shares of Kronos Bio in a report on Wednesday, September 14th. They set a “buy” rating and a $12.00 price target for the company. Piper Sandler reduced their price objective on shares of Kronos Bio from $13.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 9th. Finally, The Goldman Sachs Group reduced their price objective on shares of Kronos Bio from $25.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, November 10th.

Kronos Bio Stock Down 1.8 %

Kronos Bio stock opened at $2.13 on Monday. Kronos Bio has a 52-week low of $2.11 and a 52-week high of $15.80. The firm has a fifty day moving average of $3.16 and a 200-day moving average of $3.84. The firm has a market capitalization of $121.19 million, a P/E ratio of -0.72 and a beta of 1.29.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Acadian Asset Management LLC bought a new position in shares of Kronos Bio in the 1st quarter worth about $25,000. Amalgamated Bank bought a new position in shares of Kronos Bio in the 1st quarter worth about $35,000. Quantbot Technologies LP lifted its position in shares of Kronos Bio by 148.0% in the 1st quarter. Quantbot Technologies LP now owns 6,695 shares of the company’s stock worth $48,000 after buying an additional 3,995 shares during the last quarter. Algert Global LLC bought a new position in shares of Kronos Bio in the 3rd quarter worth about $34,000. Finally, PDT Partners LLC bought a new position in shares of Kronos Bio in the 1st quarter worth about $75,000. 62.62% of the stock is currently owned by institutional investors.

Kronos Bio Company Profile

(Get Rating)

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.

Featured Stories

Earnings History and Estimates for Kronos Bio (NASDAQ:KRON)

Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.